View Older Stories View More Recent Stories
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
AstraZeneca's (AZN) Imfinzi granted Priority Review in the US for patients with muscle-invasive bladder cancer
-
AstraZeneca (AZN): IMFINZI approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
-
AstraZeneca (AZN) Imfinzi approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
-
AstraZeneca (AZN) Appoints Iskra Reic as EVP, International
-
AstraZeneca (AZN) Reports TRUQAP combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic
-
UBS Upgrades AstraZeneca (AZN:LN) (AZN) to Neutral
-
AstraZeneca (AZN) PT Raised to $87 at Leerink Partners
-
AstraZeneca (AZN) call put ratio 1 call to 4.6 puts into quarter results
-
AstraZeneca (AZN) PT Lowered to $88 at BMO Capital
-
AstraZeneca (AZN) Tops Q3 EPS by $1.06
-
AstraZeneca (AZN) invests $3.5B in R&D and manufacturing in the US
-
AstraZeneca (AZN) reports TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial
-
Deutsche Bank Upgrades AstraZeneca (AZN:LN) (AZN) to Hold
-
TD Cowen Reiterates Buy Rating on AstraZeneca (AZN)
-
AstraZeneca (AZN) China President Leon Wang Said To Be Still Detained - Bloomberg
-
AstraZeneca (AZN) comments on share price movements
-
AstraZeneca (AZN) Insurance Fraud Involves Dozens of Senior Executives in China - Report
-
AstraZeneca (AZN) China President currently under investigation
-
AstraZeneca (AZN) reports Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic non-small cell lung cancer
-
TD Cowen Reiterates Buy Rating on AstraZeneca (AZN)
-
AstraZeneca (AZN): AIRSUPRA demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma
-
AstraZeneca (AZN) reports Airsupra demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthm
-
AstraZeneca (AZN) entres license agreement for a pre-clinical novel lipid-lowering therapy
-
AstraZeneca (AZN): CALQUENCE granted Priority Review in the US for patients with untreated mantle cell lymphoma
-
AstraZeneca (AZN) reports Calquence granted Priority Review in the US for patients with untreated mantle cell lymphoma
-
Arcus Biosciences (RCUS) Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
-
AstraZeneca (AZN): ENHERTU granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer
-
AstraZeneca's (AZN) ENHERTU Granted Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer
-
Erste Group Downgrades AstraZeneca (AZN) to Hold
-
AstraZeneca (AZN): TAGRISSO approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
-
AstraZeneca (AZN) announces Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
-
Barclays on Gilead Sciences (GILD): 'Modest positive read-through for Trodelvy positioning in 2L+ HR/Her2- breast cancer'
-
AstraZeneca (AZN)
-
AstraZeneca (AZN) announces FluMist approved for self-administration in the US
-
AstraZeneca (AZN): FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
-
AstraZeneca's (AZN) Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis
-
AstraZeneca (AZN): IMFINZI plus IMJUDO demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
-
AstraZeneca (AZN) reports Imfinzi plus Imjudo demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
-
AstraZeneca (AZN) Reports ENHERTU showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases
-
Deutsche Bank Downgrades AstraZeneca (AZN:LN) (AZN) to Sell
-
BioInvent Announces the Enrollment of the First Patient in Triple Combination Arm of BI-1206, Rituximab and Calquence(R) for the Treatment of non-Hodgkin's Lymphoma
-
BMO Capital Reiterates Outperform Rating on AstraZeneca (AZN)
-
Erste Group Upgrades AstraZeneca (AZN) to Buy
-
SOPHiA GENETICS (SOPH) and AstraZeneca (AZN) Partner to Further Expand Global Access to Liquid Biopsy Testing
-
BofA Securities Reiterates Buy Rating on AstraZeneca (AZN), PT $91.70, 'TL-01 final OS underwhelms', Shares down ~2.3%
-
AstraZeneca (AZN) Shares Down 3%+ Following Update
-
AstraZeneca (AZN) Shares Down ~2.5% Following Update
-
AstraZeneca (AZN) reports datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
-
AstraZeneca (AZN) completes clinical programme to support the transition of Breztri to next-generation propellant with near-zero Global Warming Potential
